Chimeric peptides for neuropeptide delivery through the blood-brain barrier
Patent 4902505 Issued on February 20, 1990. Estimated Expiration Date: 
April 25, 2008. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
April 25, 2008. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesMethod and system for the controlled release of biologically active substances to a body fluid Cytotoxic compositions of transferrin coupled to vinca alkaloids Patent #: 4522750 InventorsAssigneeApplicationNo. 185702 filed on 04/25/1988US Classes:424/85.7, Alpha or leukocyte514/2, Peptide containing (e.g., protein, peptones, fibrinogen, etc.) DOAI514/3, Insulin or derivative514/4, With an additional active ingredient530/302, Endorphin and Enkephalin; related peptides530/303, Insulin; related peptides530/311, Somatostatin (SRIF); related peptides530/350, PROTEINS, I.E., MORE THAN 100 AMINO ACID RESIDUES530/351Lymphokines, e.g., interferons, interlukins, etc.ExaminersPrimary: Hazel, BlondelAttorney, Agent or FirmForeign Patent References
International ClassesA61K 045/02A61K 037/02 C07K 017/00 C07K 007/00 AbstractChimeric peptides adapted for delivering neuropharmaceutical agents, such as neuropeptides into the brain by receptor-mediated transcytosis through the blood-brain barrier. The chimeric peptides include a peptide which by itself is capable of crossing the blood-brain barrier by transcytosis at a relatively high rate. The transportable peptide is conjugated to a hydrophilic neuropeptide which by itself is transportable only at a very low rate into the brain across the blood-brain barrier. The resulting chimeric peptide is transported into the brain at a much higher rate than the neuropeptide alone to thereby provide an effective means for introducing hydrophilic neuropeptides into the brain through the blood-brain barrier.Other References
Field of SearchAlpha or leukocyteWith an additional active ingredient Peptide containing (e.g., protein, peptones, fibrinogen, etc.) DOAI Insulin or derivative Endorphin and Enkephalin; related peptides Insulin; related peptides Glycoprotein, e.g., mucins proteoglycans, etc. PROTEINS, I.E., MORE THAN 100 AMINO ACID RESIDUES Lymphokines, e.g., interferons, interlukins, etc. Somatostatin (SRIF); related peptides Oxytocin; vasopressin; related peptides Peptides with at least one nonpeptide bond other than a disulfide bond joining two or more sequences of amino acid residues, e.g., homomeric heterodectic peptide other than cyclic disulfide, depsipeptides, etc. Chemical modification or the reaction product thereof, e.g., covalent attachment or coupling, etc. |
| ||||||||||||||
